Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

Understanding and reducing the experimental variability of in vitro plasma protein binding measurements.

Wang H, Zrada M, Anderson K, Katwaru R, Harradine P, Choi B, Tong V, Pajkovic N, Mazenko R, Cox K, Cohen LH.

J Pharm Sci. 2014 Oct;103(10):3302-9. doi: 10.1002/jps.24119. Epub 2014 Aug 12.

PMID:
25116691
2.

High-throughput screening of protein binding by equilibrium dialysis combined with liquid chromatography and mass spectrometry.

Wan H, Rehngren M.

J Chromatogr A. 2006 Jan 13;1102(1-2):125-34. Epub 2005 Nov 2.

PMID:
16266710
3.

Impact of pH on plasma protein binding in equilibrium dialysis.

Kochansky CJ, McMasters DR, Lu P, Koeplinger KA, Kerr HH, Shou M, Korzekwa KR.

Mol Pharm. 2008 May-Jun;5(3):438-48. doi: 10.1021/mp800004s. Epub 2008 Mar 18.

PMID:
18345638
4.

Protein binding in antiretroviral therapies.

Boffito M, Back DJ, Blaschke TF, Rowland M, Bertz RJ, Gerber JG, Miller V.

AIDS Res Hum Retroviruses. 2003 Sep;19(9):825-35. Review.

PMID:
14585213
5.
6.

Protein-binding characteristics of voriconazole determined by high-throughput equilibrium dialysis.

Vanstraelen K, Wauters J, De Loor H, Vercammen I, Annaert P, Lagrou K, Spriet I.

J Pharm Sci. 2014 Aug;103(8):2565-70. doi: 10.1002/jps.24064. Epub 2014 Jun 24.

PMID:
24961809
7.

Validation of 96-well equilibrium dialysis with non-radiolabeled drug for definitive measurement of protein binding and application to clinical development of highly-bound drugs.

Zamek-Gliszczynski MJ, Ruterbories KJ, Ajamie RT, Wickremsinhe ER, Pothuri L, Rao MV, Basavanakatti VN, Pinjari J, Ramanathan VK, Chaudhary AK.

J Pharm Sci. 2011 Jun;100(6):2498-507. doi: 10.1002/jps.22452. Epub 2011 Jan 6.

PMID:
21213309
8.
9.

Development and validation of a higher-throughput equilibrium dialysis assay for plasma protein binding.

van Liempd S, Morrison D, Sysmans L, Nelis P, Mortishire-Smith R.

J Lab Autom. 2011 Feb;16(1):56-67. doi: 10.1016/j.jala.2010.06.002. Epub 2011 Jan 12.

PMID:
21609686
10.

Quantitative analysis of PD 0332991 in mouse plasma using automated micro-sample processing and microbore liquid chromatography coupled with tandem mass spectrometry.

Smith D, Tella M, Rahavendran SV, Shen Z.

J Chromatogr B Analyt Technol Biomed Life Sci. 2011 Oct 1;879(27):2860-5. doi: 10.1016/j.jchromb.2011.08.009. Epub 2011 Aug 16.

PMID:
21889427
11.

Pethidine binding in plasma: effects of methodological variables.

La Rosa C, Mather LE, Morgan DJ.

Br J Clin Pharmacol. 1984 Apr;17(4):411-5.

12.

Control and measurement of plasma pH in equilibrium dialysis: influence on drug plasma protein binding.

Curran RE, Claxton CR, Hutchison L, Harradine PJ, Martin IJ, Littlewood P.

Drug Metab Dispos. 2011 Mar;39(3):551-7. doi: 10.1124/dmd.110.036988. Epub 2010 Nov 23.

13.

Validation of a rapid equilibrium dialysis approach for the measurement of plasma protein binding.

Waters NJ, Jones R, Williams G, Sohal B.

J Pharm Sci. 2008 Oct;97(10):4586-95. doi: 10.1002/jps.21317.

PMID:
18300299
14.

Determination of unbound ticagrelor and its active metabolite (AR-C124910XX) in human plasma by equilibrium dialysis and LC-MS/MS.

Sillén H, Cook M, Davis P.

J Chromatogr B Analyt Technol Biomed Life Sci. 2011 Aug 1;879(23):2315-22. doi: 10.1016/j.jchromb.2011.06.023. Epub 2011 Jun 21.

PMID:
21727045
15.

An integrated bioanalytical platform for supporting high-throughput serum protein binding screening.

Zhang J, Shou WZ, Vath M, Kieltyka K, Maloney J, Elvebak L, Stewart J, Herbst J, Weller HN.

Rapid Commun Mass Spectrom. 2010 Dec 30;24(24):3593-601. doi: 10.1002/rcm.4817.

PMID:
21080511
16.

Implications of plasma protein binding for pharmacokinetics and pharmacodynamics of the γ-secretase inhibitor RO4929097.

Wu J, Lorusso PM, Matherly LH, Li J.

Clin Cancer Res. 2012 Apr 1;18(7):2066-79. doi: 10.1158/1078-0432.CCR-11-2684. Epub 2012 Feb 20.

17.

The pH dependency of the binding of drugs to plasma proteins in man.

Hinderling PH, Hartmann D.

Ther Drug Monit. 2005 Feb;27(1):71-85.

PMID:
15665750
18.

Plasma protein binding, pharmacokinetics, tissue distribution and CYP450 biotransformation studies of fidarestat by ultra high performance liquid chromatography-high resolution mass spectrometry.

Borkar RM, Bhandi MM, Dubey AP, Nandekar PP, Sangamwar AT, Banerjee SK, Srinivas R.

J Pharm Biomed Anal. 2015 Jan;102:386-99. doi: 10.1016/j.jpba.2014.10.008. Epub 2014 Oct 19.

PMID:
25459938
19.

Preclinical pharmacokinetics: an approach towards safer and efficacious drugs.

Singh SS.

Curr Drug Metab. 2006 Feb;7(2):165-82. Review.

PMID:
16472106
20.

Single and multiple dose intravenous and oral pharmacokinetics of the hedgehog pathway inhibitor vismodegib in healthy female subjects.

Graham RA, Hop CE, Borin MT, Lum BL, Colburn D, Chang I, Shin YG, Malhi V, Low JA, Dresser MJ.

Br J Clin Pharmacol. 2012 Nov;74(5):788-96. doi: 10.1111/j.1365-2125.2012.04281.x.

Supplemental Content

Support Center